Dimensional Fund Advisors LP increased its holdings in Pfenex Inc (NYSEMKT:PFNX) by 249.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 94,809 shares of the biotechnology company’s stock after purchasing an additional 67,640 shares during the quarter. Dimensional Fund Advisors LP owned 0.41% of Pfenex worth $551,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in PFNX. Russell Investments Group Ltd. lifted its stake in shares of Pfenex by 221.0% in the first quarter. Russell Investments Group Ltd. now owns 32,186 shares of the biotechnology company’s stock worth $187,000 after buying an additional 22,160 shares during the last quarter. Algert Global LLC raised its stake in Pfenex by 207.3% during the 1st quarter. Algert Global LLC now owns 34,603 shares of the biotechnology company’s stock valued at $201,000 after purchasing an additional 23,344 shares during the last quarter. Nine Chapters Capital Management LLC acquired a new position in Pfenex during the 1st quarter valued at $265,000. Spark Investment Management LLC acquired a new position in Pfenex during the 1st quarter valued at $439,000. Finally, TFS Capital LLC raised its stake in shares of Pfenex by 101.1% in the 1st quarter. TFS Capital LLC now owns 97,093 shares of the biotechnology company’s stock valued at $564,000 after buying an additional 48,805 shares in the last quarter.
Pfenex Inc (NYSEMKT PFNX) traded down 1.364% during mid-day trading on Friday, hitting $3.255. The stock had a trading volume of 13,626 shares. The firm has a market cap of $76.58 million, a PE ratio of 52.500 and a beta of 4.65. The company’s 50 day moving average price is $3.73 and its 200 day moving average price is $4.71. Pfenex Inc has a 52 week low of $3.16 and a 52 week high of $11.35.
Pfenex (NYSEMKT:PFNX) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.52) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.06). Pfenex had a negative net margin of 406.87% and a negative return on equity of 75.61%. The firm had revenue of $3.03 million for the quarter, compared to the consensus estimate of $3.10 million. During the same quarter in the prior year, the firm earned ($0.43) earnings per share. The company’s revenue for the quarter was down 3.5% compared to the same quarter last year. Analysts anticipate that Pfenex Inc will post ($2.09) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This piece was published by BBNS and is owned by of BBNS. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://baseballnewssource.com/markets/dimensional-fund-advisors-lp-acquires-67640-shares-of-pfenex-inc-pfnx/1603863.html.
Several brokerages have recently issued reports on PFNX. Zacks Investment Research raised shares of Pfenex from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research note on Thursday, July 13th. William Blair reaffirmed an “ourperform” rating on shares of Pfenex in a research note on Friday, September 8th. Finally, ValuEngine cut shares of Pfenex from a “hold” rating to a “sell” rating in a research report on Saturday, June 3rd.
Pfenex Inc is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab).
Receive News & Ratings for Pfenex Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex Inc and related companies with our FREE daily email newsletter.